Market closed
Phathom Pharmaceuticals/$PHAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
427
Website
PHAT Metrics
BasicAdvanced
$342M
-
-$5.29
0.64
-
Price and volume
Market cap
$342M
Beta
0.64
52-week high
$18.68
52-week low
$4.33
Average daily volume
1.1M
Financial strength
Current ratio
4.201
Quick ratio
3.92
Long term debt to equity
-210.849
Total debt to equity
-218.845
Interest coverage (TTM)
-3.85%
Management effectiveness
Return on assets (TTM)
-43.78%
Return on equity (TTM)
204.89%
Valuation
Price to revenue (TTM)
5.717
Price to book
-1.35
Price to tangible book (TTM)
-1.35
Price to free cash flow (TTM)
-1.183
Growth
Revenue change (TTM)
8,001.47%
Earnings per share change (TTM)
34.64%
3-year earnings per share growth (CAGR)
10.82%
What the Analysts think about PHAT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
PHAT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PHAT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PHAT News
AllArticlesVideos
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·1 week ago
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $342M as of March 14, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of March 14, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.